Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Seminars in Immunopathology
Erschienen in: Seminars in Immunopathology 4/2022

24.02.2022 | Review

Th17 cells in the liver: balancing autoimmunity and pathogen defense

verfasst von: Nobuhito Taniki, Nobuhiro Nakamoto, Po-Sung Chu, Masataka Ichikawa, Toshiaki Teratani, Takanori Kanai

Erschienen in: Seminars in Immunopathology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

In addition to carcinogenesis, T helper 17 (Th17) cells (a subtype of CD4 + T lymphocytes) are involved in the acute, chronic, and cirrhotic phases of liver diseases; however, their role in the development and progression of liver diseases remains unclear. It is difficult to elucidate the role of Th17 cells in liver diseases due to their dichotomous nature, i.e., plasticity in terms of pathogenic or host protective function depending on environmental and time phase factors. Moreover, insufficient depletion of Th17 cells by inhibiting the cytokines and transcription factors involved in their production causes difficulties in analyzing their specific role in vitro and in vivo murine models, partially due to complex interaction. This review summarizes the recent progress in understanding the plasticity and function of hepatic Th17 cells and type 3 cytokines.
Literatur
1.
Dong C (2008) IL-23/IL-17 biology and therapeutic considerations. J Immunotoxicol 5(1):43–46PubMedCrossRef
2.
Diveu C, McGeachy MJ, Cua DJ (2008) Cytokines that regulate autoimmunity. Curr Opin Immunol 20(6):663–668PubMedCrossRef
3.
Oo YH, Banz V, Kavanagh D, Liaskou E, Withers DR, Humphreys E, Reynolds GM, Lee-Turner L, Kalia N, Hubscher SG, Klenerman P, Eksteen B, Adams DH (2012) CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol 57(5):1044–1051PubMedPubMedCentralCrossRef
4.
5.
6.
Thomson AW, Knolle PA (2010) Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 10(11):753–766PubMedCrossRef
7.
Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P (1993) CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 150(12):5445–5456PubMed
8.
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6(11):1123–1132PubMedCrossRef
9.
Tuomela S, Rautio S, Ahlfors H, Oling V, Salo V, Ullah U, Chen Z, Hamalisto S, Tripathi SK, Aijo T, Rasool O, Soueidan H, Wessels L, Stockinger B, Lahdesmaki H, Lahesmaa R (2016) Comparative analysis of human and mouse transcriptomes of Th17 cell priming. Oncotarget 7(12):13416–13428PubMedPubMedCentralCrossRef
10.
Ivanov BS II, McKenzie L, Zhou CE, Tadokoro A, Lepelley JJ, Lafaille DJ, Cua DR (2006) Littman, The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126(6):1121–1133PubMedCrossRef
11.
Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F, Agarwal A, Huang W, Parkhurst CN, Muratet M, Newberry KM, Meadows S, Greenfield A, Yang Y, Jain P, Kirigin FK, Birchmeier C, Wagner EF, Murphy KM, Myers RM, Bonneau R, Littman DR (2012) A validated regulatory network for Th17 cell specification. Cell 151(2):289–303PubMedPubMedCentralCrossRef
12.
Tanaka S, Suto A, Iwamoto T, Kashiwakuma D, Kagami S, Suzuki K, Takatori H, Tamachi T, Hirose K, Onodera A, Suzuki J, Ohara O, Yamashita M, Nakayama T, Nakajima H (2014) Sox5 and c-Maf cooperatively induce Th17 cell differentiation via RORgammat induction as downstream targets of Stat3. J Exp Med 211(9):1857–1874PubMedPubMedCentralCrossRef
13.
Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8(9):942–949PubMedCrossRef
14.
Jain R, Chen Y, Kanno Y, Joyce-Shaikh B, Vahedi G, Hirahara K, Blumenschein WM, Sukumar S, Haines CJ, Sadekova S, McClanahan TK, McGeachy MJ, O’Shea JJ, Cua DJ (2016) Interleukin-23-induced transcription factor blimp-1 promotes pathogenicity of T helper 17 cells. Immunity 44(1):131–142PubMedCrossRef
15.
Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238PubMedCrossRef
16.
Yamazaki T, Yang XO, Chung Y, Fukunaga A, Nurieva R, Pappu B, Martin-Orozco N, Kang HS, Ma L, Panopoulos AD, Craig S, Watowich SS, Jetten AM, Tian Q, Dong C (2008) CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol 181(12):8391–8401PubMedCrossRef
17.
Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters MJ, Tomkinson KN, Fitz LJ, Wolfman NM, Collins M, Dunussi-Joannopoulos K, Chatterjee-Kishore M, Carreno BM (2008) The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol 181(4):2799–2805PubMedCrossRef
18.
19.
Cua DJ, Tato CM (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10(7):479–489PubMedCrossRef
20.
Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, Lee KH, Gehring AJ, De Libero G, Bertoletti A (2013) IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol 190(7):3142–3152PubMedCrossRef
21.
Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, Louis D, Milder M, Le Bourhis L, Soudais C, Treiner E, Lantz O (2011) Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 117(4):1250–1259PubMedCrossRef
22.
Walker LJ, Kang YH, Smith MO, Tharmalingham H, Ramamurthy N, Fleming VM, Sahgal N, Leslie A, Oo Y, Geremia A, Scriba TJ, Hanekom WA, Lauer GM, Lantz O, Adams DH, Powrie F, Barnes E, Klenerman P (2012) Human MAIT and CD8alphaalpha cells develop from a pool of type-17 precommitted CD8+ T cells. Blood 119(2):422–433PubMedPubMedCentralCrossRef
23.
Dumoutier L, Van Roost E, Colau D, Renauld JC (2000) Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci U S A 97(18):10144–10149PubMedPubMedCentralCrossRef
24.
Dumoutier L, Van Roost E, Ameye G, Michaux L, Renauld JC (2000) IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun 1(8):488–494PubMedCrossRef
25.
K.W. Moore, R. de Waal Malefyt, R.L. Coffman, A. O'Garra, Interleukin-10 and the interleukin-10 receptor, Annu Rev Immunol 19 (2001) 683–765.
26.
Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29:71–109PubMedCrossRef
27.
28.
Savage AK, Liang HE, Locksley RM (2017) The development of steady-state activation hubs between adult LTi ILC3s and primed macrophages in small intestine. J Immunol 199(5):1912–1922PubMedCrossRef
29.
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R (2004) IL-22 increases the innate immunity of tissues. Immunity 21(2):241–254PubMedCrossRef
30.
Rutz S, Wang X, Ouyang W (2014) The IL-20 subfamily of cytokines–from host defence to tissue homeostasis. Nat Rev Immunol 14(12):783–795PubMedCrossRef
31.
Sonnenberg GF, Fouser LA, Artis D (2011) Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 12(5):383–390PubMedCrossRef
32.
Rutz S, Noubade R, Eidenschenk C, Ota N, Zeng W, Zheng Y, Hackney J, Ding J, Singh H, Ouyang W (2011) Transcription factor c-Maf mediates the TGF-beta-dependent suppression of IL-22 production in T(H)17 cells. Nat Immunol 12(12):1238–1245PubMedCrossRef
33.
Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, Pestka S (2001) Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 276(4):2725–2732PubMedCrossRef
34.
Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, Wood WI, Goddard AD, Gurney AL (2000) Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 275(40):31335–31339PubMedCrossRef
35.
36.
P.R. Burkett, G. Meyer zu Horste, V.K. Kuchroo, Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity, The Journal of clinical investigation 125(6) (2015) 2211–9.
37.
Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A, Sallusto F (2012) Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 484(7395):514–518PubMedCrossRef
38.
Duhen T, Campbell DJ (2014) IL-1beta promotes the differentiation of polyfunctional human CCR6+CXCR3+ Th1/17 cells that are specific for pathogenic and commensal microbes. J Immunol 193(1):120–129PubMedCrossRef
39.
Sujino T, Kanai T, Ono Y, Mikami Y, Hayashi A, Doi T, Matsuoka K, Hisamatsu T, Takaishi H, Ogata H, Yoshimura A, Littman DR, Hibi T (2011) Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells. Gastroenterology 141(3):1014–1023PubMedCrossRef
40.
L. Cosmi, L. Maggi, V. Santarlasci, M. Capone, E. Cardilicchia, F. Frosali, V. Querci, R. Angeli, A. Matucci, M. Fambrini, F. Liotta, P. Parronchi, E. Maggi, S. Romagnani, F. Annunziato, Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4, J Allergy Clin Immunol 125(1) (2010) 222–30 e1–4.
41.
Stritesky GL, Yeh N, Kaplan MH (2008) IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 181(9):5948–5955PubMedCrossRef
42.
43.
Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, Weaver CT (2009) Late developmental plasticity in the T helper 17 lineage. Immunity 30(1):92–107PubMedPubMedCentralCrossRef
44.
Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204(8):1849–1861PubMedPubMedCentralCrossRef
45.
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278(3):1910–1914PubMedCrossRef
46.
Ahern PP, Schiering C, Buonocore S, McGeachy MJ, Cua DJ, Maloy KJ, Powrie F (2010) Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33(2):279–288PubMedPubMedCentralCrossRef
47.
Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wilhelm C, Tolaini M, Menzel U, Garefalaki A, Potocnik AJ, Stockinger B (2011) Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 12(3):255–263PubMedPubMedCentralCrossRef
48.
49.
Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485–517PubMedCrossRef
50.
51.
52.
Hernandez-Santos N, Huppler AR, Peterson AC, Khader SA, McKenna KC, Gaffen SL (2013) Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections. Mucosal Immunol 6(5):900–910PubMedCrossRef
53.
54.
Conti HR, Gaffen SL (2015) IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol 195(3):780–788PubMedCrossRef
55.
Drummond RA, Lionakis MS (2019) Organ-specific mechanisms linking innate and adaptive antifungal immunity. Semin Cell Dev Biol 89:78–90PubMedCrossRef
56.
J. Li, J.L. Casanova, A. Puel, Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation, Mucosal Immunol 11(3) (2018) 581–589.
57.
Hamada S, Umemura M, Shiono T, Tanaka K, Yahagi A, Begum MD, Oshiro K, Okamoto Y, Watanabe H, Kawakami K, Roark C, Born WK, O’Brien R, Ikuta K, Ishikawa H, Nakae S, Iwakura Y, Ohta T, Matsuzaki G (2008) IL-17A produced by gammadelta T cells plays a critical role in innate immunity against listeria monocytogenes infection in the liver. J Immunol 181(5):3456–3463PubMedCrossRef
58.
Schulz SM, Kohler G, Holscher C, Iwakura Y, Alber G (2008) IL-17A is produced by Th17, gammadelta T cells and other CD4- lymphocytes during infection with Salmonella enterica serovar Enteritidis and has a mild effect in bacterial clearance. Int Immunol 20(9):1129–1138PubMedCrossRef
59.
C. Wang, N. Yosef, J. Gaublomme, C. Wu, Y. Lee, C.B. Clish, J. Kaminski, S. Xiao, G. Meyer Zu Horste, M. Pawlak, Y. Kishi, N. Joller, K. Karwacz, C. Zhu, M. Ordovas-Montanes, A. Madi, I. Wortman, T. Miyazaki, R.A. Sobel, H. Park, A. Regev, V.K. Kuchroo, CD5L/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity, Cell 163(6) (2015) 1413–27.
60.
Saraiva M, O’Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10(3):170–181PubMedCrossRef
61.
Evans HG, Roostalu U, Walter GJ, Gullick NJ, Frederiksen KS, Roberts CA, Sumner J, Baeten DL, Gerwien JG, Cope AP, Geissmann F, Kirkham BW, Taams LS (2014) TNF-alpha blockade induces IL-10 expression in human CD4+ T cells. Nat Commun 5:3199PubMedCrossRef
62.
Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O’Connor W Jr, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone JA, Herold KC, Flavell RA (2011) Control of TH17 cells occurs in the small intestine. Nature 475(7357):514–518PubMedPubMedCentralCrossRef
63.
Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, Guo B, Herbert DR, Bulfone A, Trentini F, Di Serio C, Bacchetta R, Andreani M, Brockmann L, Gregori S, Flavell RA, Roncarolo MG (2013) Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 19(6):739–746PubMedCrossRef
64.
Bhaumik S, Basu R (2017) Cellular and molecular dynamics of Th17 differentiation and its developmental plasticity in the intestinal immune response. Front Immunol 8:254PubMedPubMedCentralCrossRef
65.
Wang C, Collins M, Kuchroo VK (2015) Effector T cell differentiation: are master regulators of effector T cells still the masters? Curr Opin Immunol 37:6–10PubMedCrossRef
66.
Shabgah AG, Navashenaq JG, Shabgah OG, Mohammadi H, Sahebkar A (2017) Interleukin-22 in human inflammatory diseases and viral infections. Autoimmun Rev 16(12):1209–1218PubMedCrossRef
67.
Xiang X, Feng D, Hwang S, Ren T, Wang X, Trojnar E, Matyas C, Mo R, Shang D, He Y, Seo W, Shah VH, Pacher P, Xie Q, Gao B (2020) Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. J Hepatol 72(4):736–745PubMedCrossRef
68.
Yasumi Y, Takikawa Y, Endo R, Suzuki K (2007) Interleukin-17 as a new marker of severity of acute hepatic injury, Hepatology research : the official journal of the Japan Society of. Hepatology 37(4):248–254CrossRef
69.
Lai R, Xiang X, Mo R, Bao R, Wang P, Guo S, Zhao G, Gui H, Wang H, Bao S, Xie Q (2015) Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury. J Hepatol 63(1):148–155PubMedCrossRef
70.
Beringer A, Miossec P (2018) IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases. Autoimmun Rev 17(12):1176–1185PubMedCrossRef
71.
72.
L. Zhao, Y. Tang, Z. You, Q. Wang, S. Liang, X. Han, D. Qiu, J. Wei, Y. Liu, L. Shen, X. Chen, Y. Peng, Z. Li, X. Ma, Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression, PloS one 6(4) (2011) e18909.
73.
Patel DN, King CA, Bailey SR, Holt JW, Venkatachalam K, Agrawal A, Valente AJ, Chandrasekar B (2007) Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 282(37):27229–27238PubMedCrossRef
74.
F. Meng, K. Wang, T. Aoyama, S.I. Grivennikov, Y. Paik, D. Scholten, M. Cong, K. Iwaisako, X. Liu, M. Zhang, C.H. Osterreicher, F. Stickel, K. Ley, D.A. Brenner, T. Kisseleva, Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice, Gastroenterology 143(3) (2012) 765–776 e3.
75.
Amara S, Lopez K, Banan B, Brown SK, Whalen M, Myles E, Ivy MT, Johnson T, Schey KL, Tiriveedhi V (2015) Synergistic effect of pro-inflammatory TNFalpha and IL-17 in periostin mediated collagen deposition: potential role in liver fibrosis. Mol Immunol 64(1):26–35PubMedCrossRef
76.
Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y (2009) Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 157(2):261–270PubMedPubMedCentralCrossRef
77.
Huang Q, Chu S, Yin X, Yu X, Kang C, Li X, Qiu Y (2016) Interleukin-17A-induced epithelial-mesenchymal transition of human intrahepatic biliary epithelial cells: implications for primary biliary cirrhosis. Tohoku J Exp Med 240(4):269–275PubMedCrossRef
78.
H.C. Jeffery, S. Hunter, E.H. Humphreys, R. Bhogal, R.E. Wawman, J. Birtwistle, M. Atif, C.J. Bagnal, G. Rodriguez Blanco, N. Richardson, S. Warner, W.B. Dunn, S.C. Afford, D.H. Adams, Y.H. Oo, Bidirectional cross-talk between biliary epithelium and Th17 Cells promotes local Th17 expansion and bile duct proliferation in biliary liver diseases, J Immunol 203(5) (2019) 1151–1159.
79.
Heymann F, Tacke F (2016) Immunology in the liver–from homeostasis to disease. Nat Rev Gastroenterol Hepatol 13(2):88–110PubMedCrossRef
80.
F. Lafdil, H. Wang, O. Park, W. Zhang, Y. Moritoki, S. Yin, X.Y. Fu, M.E. Gershwin, Z.X. Lian, B. Gao, Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production, Gastroenterology 137(6) (2009) 2125–35 e1–2.
81.
Zhang Y, Wang X, Zhong M, Zhang M, Suo Q, Lv K (2013) MicroRNA let-7a ameliorates con A-induced hepatitis by inhibiting IL-6-dependent Th17 cell differentiation. J Clin Immunol 33(3):630–639PubMedCrossRef
82.
Yan S, Wang L, Liu N, Wang Y, Chu Y (2012) Critical role of interleukin-17/interleukin-17 receptor axis in mediating Con A-induced hepatitis. Immunol Cell Biol 90(4):421–428PubMedCrossRef
83.
Xu M, Morishima N, Mizoguchi I, Chiba Y, Fujita K, Kuroda M, Iwakura Y, Cua DJ, Yasutomo K, Mizuguchi J, Yoshimoto T (2011) Regulation of the development of acute hepatitis by IL-23 through IL-22 and IL-17 production. Eur J Immunol 41(10):2828–2839PubMedCrossRef
84.
Furuya S, Kono H, Hara M, Hirayama K, Sun C, Fujii H (2015) Interleukin 17A plays a role in lipopolysaccharide/D-galactosamine-induced fulminant hepatic injury in mice. J Surg Res 199(2):487–493PubMedCrossRef
85.
Wondimu Z, Santodomingo-Garzon T, Le T, Swain MG (2010) Protective role of interleukin-17 in murine NKT cell-driven acute experimental hepatitis. Am J Pathol 177(5):2334–2346PubMedPubMedCentralCrossRef
86.
Radaeva S, Sun R, Pan HN, Hong F, Gao B (2004) Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39(5):1332–1342PubMedCrossRef
87.
Wahl C, Wegenka UM, Leithauser F, Schirmbeck R, Reimann J (2009) IL-22-dependent attenuation of T cell-dependent (ConA) hepatitis in herpes virus entry mediator deficiency. J Immunol 182(8):4521–4528PubMedCrossRef
88.
Pan H, Hong F, Radaeva S, Gao B (2004) Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 1(1):43–49PubMed
89.
Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, Ki SH, Yoo SH, Dooley S, Wang FS, Young HA, Gao B (2011) In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 54(1):252–261PubMedCrossRef
90.
Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA (2007) Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 27(4):647–659PubMedPubMedCentralCrossRef
91.
Gialitakis M, Tolaini M, Li Y, Pardo M, Yu L, Toribio A, Choudhary JS, Niakan K, Papayannopoulos V, Stockinger B (2017) Activation of the aryl hydrocarbon receptor interferes with early embryonic development. Stem Cell Reports 9(5):1377–1386PubMedPubMedCentralCrossRef
92.
Poland A, Glover E, Kende AS (1976) Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase, J Biol Chem 251(16):4936–4946PubMed
93.
Poland A, Knutson JC (1982) 2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Pharmacol Toxicol 22:517–554PubMedCrossRef
94.
Ema M, Sogawa K, Watanabe N, Chujoh Y, Matsushita N, Gotoh O, Funae Y, Fujii-Kuriyama Y (1992) cDNA cloning and structure of mouse putative Ah receptor. Biochem Biophys Res Commun 184(1):246–253PubMedCrossRef
95.
Hubbard TD, Murray IA, Perdew GH (2015) Indole and tryptophan metabolism: endogenous and dietary routes to Ah receptor activation. Drug Metab Dispos 43(10):1522–1535PubMedPubMedCentralCrossRef
96.
97.
A. Matsumoto, T. Kanai, Y. Mikami, P.S. Chu, N. Nakamoto, H. Ebinuma, H. Saito, T. Sato, H. Yagita, T. Hibi, IL-22-producing RORgammat-dependent innate lymphoid cells play a novel protective role in murine acute hepatitis, PLoS One 8(4) (2013) e62853.
98.
M.L. Balmer, E. Slack, A. de Gottardi, M.A. Lawson, S. Hapfelmeier, L. Miele, A. Grieco, H. Van Vlierberghe, R. Fahrner, N. Patuto, C. Bernsmeier, F. Ronchi, M. Wyss, D. Stroka, N. Dickgreber, M.H. Heim, K.D. McCoy, A.J. Macpherson, The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota, Sci Transl Med 6(237) (2014) 237ra66.
99.
Y. Mikami, S. Mizuno, N. Nakamoto, A. Hayashi, T. Sujino, T. Sato, N. Kamada, K. Matsuoka, T. Hisamatsu, H. Ebinuma, T. Hibi, A. Yoshimura, T. Kanai, Macrophages and dendritic cells emerge in the liver during intestinal inflammation and predispose the liver to inflammation, PLoS One 9(1) (2014) e84619.
100.
N. Taniki, N. Nakamoto, P.S. Chu, Y. Mikami, T. Amiya, T. Teratani, T. Suzuki, T. Tsukimi, S. Fukuda, A. Yamaguchi, S. Shiba, R. Miyake, T. Katayama, H. Ebinuma, T. Kanai, Intestinal barrier regulates immune responses in the liver via IL-10-producing macrophages, JCI Insight 3(12) (2018).
101.
Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N, Grainger JR, Chen Q, Kanno Y, Watford WT, Sun HW, Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O’Shea JJ (2010) Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 467(7318):967–971PubMedPubMedCentralCrossRef
102.
Schnupf P, Gaboriau-Routhiau V, Cerf-Bensussan N (2013) Host interactions with segmented filamentous bacteria: an unusual trade-off that drives the post-natal maturation of the gut immune system. Semin Immunol 25(5):342–351PubMedCrossRef
103.
V. Patel, S. Lee, M. McPhail, K. Da Silva, S. Guilly, A. Zamalloa, E. Witherden, S. Stoy, G.K. Manakkat Vijay, N. Pons, N. Galleron, X. Huang, S. Gencer, M. Coen, T.H. Tranah, J.A. Wendon, K. Bruce, E. Le Chatelier, S.D. Ehrlich, L.A. Edwards, S. Shoaie, D.L. Shawcross, Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial, J Hepatol (2021).
104.
L. Craven, A. Rahman, S. Nair Parvathy, M. Beaton, J. Silverman, K. Qumosani, I. Hramiak, R. Hegele, T. Joy, J. Meddings, B. Urquhart, R. Harvie, C. McKenzie, K. Summers, G. Reid, J.P. Burton, M. Silverman, Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial, Am J Gastroenterol 115(7) (2020) 1055–1065.
105.
H.J. Wu, Ivanov, II, J. Darce, K. Hattori, T. Shima, Y. Umesaki, D.R. Littman, C. Benoist, D. Mathis, Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells, Immunity 32(6) (2010) 815–27.
106.
S.G. de Aquino, S. Abdollahi-Roodsaz, M.I. Koenders, F.A. van de Loo, G.J. Pruijn, R.J. Marijnissen, B. Walgreen, M.M. Helsen, L.A. van den Bersselaar, R.S. de Molon, M.J. Avila Campos, F.Q. Cunha, J.A. Cirelli, W.B. van den Berg, Periodontal pathogens directly promote autoimmune experimental arthritis by inducing a TLR2- and IL-1-driven Th17 response, Journal of immunology 192(9) (2014) 4103–11.
107.
Maeda Y, Kurakawa T, Umemoto E, Motooka D, Ito Y, Gotoh K, Hirota K, Matsushita M, Furuta Y, Narazaki M, Sakaguchi N, Kayama H, Nakamura S, Iida T, Saeki Y, Kumanogoh A, Sakaguchi S, Takeda K (2016) Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis Rheumatol 68(11):2646–2661PubMedCrossRef
108.
Marietta EV, Murray JA, Luckey DH, Jeraldo PR, Lamba A, Patel R, Luthra HS, Mangalam A, Taneja V (2016) Suppression of inflammatory arthritis by human gut-derived prevotella histicola in humanized mice. Arthritis Rheumatol 68(12):2878–2888PubMedPubMedCentralCrossRef
109.
C.P. Bradley, F. Teng, K.M. Felix, T. Sano, D. Naskar, K.E. Block, H. Huang, K.S. Knox, D.R. Littman, H.J. Wu, Segmented filamentous bacteria provoke lung autoimmunity by inducing gut-lung axis Th17 cells expressing dual TCRs, Cell host & microbe 22(5) (2017) 697–704 e4.
110.
D. Yang, X. Chen, J. Wang, Q. Lou, Y. Lou, L. Li, H. Wang, J. Chen, M. Wu, X. Song, Y. Qian, Dysregulated Lung commensal bacteria drive interleukin-17B production to promote pulmonary fibrosis through their outer membrane vesicles, Immunity 50(3) (2019) 692–706 e7.
111.
Asquith MJ, Stauffer P, Davin S, Mitchell C, Lin P, Rosenbaum JT (2016) Perturbed mucosal immunity and dysbiosis accompany clinical disease in a rat model of spondyloarthritis. Arthritis Rheumatol 68(9):2151–2162PubMedPubMedCentralCrossRef
112.
Mangalam A, Shahi SK, Luckey D, Karau M, Marietta E, Luo N, Choung RS, Ju J, Sompallae R, Gibson-Corley K, Patel R, Rodriguez M, David C, Taneja V, Murray J (2017) Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease. Cell Rep 20(6):1269–1277PubMedPubMedCentralCrossRef
113.
114.
Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, Angelin B, Hyotylainen T, Oresic M, Backhed F (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17(2):225–235PubMedCrossRef
115.
Wahlstrom A, Sayin SI, Marschall HU, Backhed F (2016) Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 24(1):41–50PubMedCrossRef
116.
117.
O’Brien KM, Allen KM, Rockwell CE, Towery K, Luyendyk JP, Copple BL (2013) IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis. Am J Pathol 183(5):1498–1507PubMedPubMedCentralCrossRef
118.
Soroosh P, Wu J, Xue X, Song J, Sutton SW, Sablad M, Yu J, Nelen MI, Liu X, Castro G, Luna R, Crawford S, Banie H, Dandridge RA, Deng X, Bittner A, Kuei C, Tootoonchi M, Rozenkrants N, Herman K, Gao J, Yang XV, Sachen K, Ngo K, Fung-Leung WP, Nguyen S, de Leon-Tabaldo A, Blevitt J, Zhang Y, Cummings MD, Rao T, Mani NS, Liu C, McKinnon M, Milla ME, Fourie AM, Sun S (2014) Oxysterols are agonist ligands of RORgammat and drive Th17 cell differentiation. Proc Natl Acad Sci U S A 111(33):12163–12168PubMedPubMedCentralCrossRef
119.
Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L, Zheng Y, Longman RS, Rastinejad F, Devlin AS, Krout MR, Fischbach MA, Littman DR, Huh JR (2019) Bile acid metabolites control TH17 and Treg cell differentiation. Nature 576(7785):143–148PubMedPubMedCentralCrossRef
120.
Gu YZ, Hogenesch JB, Bradfield CA (2000) The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 40:519–561PubMedCrossRef
121.
Stockinger B, Di Meglio P, Gialitakis M, Duarte JH (2014) The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol 32:403–432PubMedCrossRef
122.
Ciolino HP, Daschner PJ, Wang TT, Yeh GC (1998) Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Biochem Pharmacol 56(2):197–206PubMedCrossRef
123.
Wanner R, Brommer S, Czarnetzki BM, Rosenbach T (1995) The differentiation-related upregulation of aryl hydrocarbon receptor transcript levels is suppressed by retinoic acid. Biochem Biophys Res Commun 209(2):706–711PubMedCrossRef
124.
Phelan D, Winter GM, Rogers WJ, Lam JC, Denison MS (1998) Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin. Arch Biochem Biophys 357(1):155–163PubMedCrossRef
125.
Abron JD, Singh NP, Mishra MK, Price RL, Nagarkatti M, Nagarkatti PS, Singh UP (2018) An endogenous aryl hydrocarbon receptor ligand, ITE, induces regulatory T cells and ameliorates experimental colitis. Am J Physiol Gastrointest Liver Physiol 315(2):G220–G230PubMedPubMedCentralCrossRef
126.
A. Abdullah, M. Maged, M.I. Hairul-Islam, I.A. Osama, H. Maha, A. Manal, H. Hamza, Activation of aryl hydrocarbon receptor signaling by a novel agonist ameliorates autoimmune encephalomyelitis, PloS one 14(4) (2019) e0215981.
127.
Nebert DW (2017) Aryl hydrocarbon receptor (AHR): “pioneer member” of the basic-helix/loop/helix per-Arnt-sim (bHLH/PAS) family of “sensors” of foreign and endogenous signals. Prog Lipid Res 67:38–57PubMedPubMedCentralCrossRef
128.
Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, Weiner HL (2008) Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453(7191):65–71PubMedCrossRef
129.
Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453(7191):106–109PubMedCrossRef
130.
Veldhoen M, Hirota K, Christensen J, O’Garra A, Stockinger B (2009) Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 206(1):43–49PubMedPubMedCentralCrossRef
131.
Nakahama T, Kimura A, Nguyen NT, Chinen I, Hanieh H, Nohara K, Fujii-Kuriyama Y, Kishimoto T (2011) Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis. Proc Natl Acad Sci U S A 108(34):14222–14227PubMedPubMedCentralCrossRef
132.
Qiu J, Heller JJ, Guo X, Chen ZM, Fish K, Fu YX, Zhou L (2012) The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 36(1):92–104PubMedCrossRef
133.
Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, Hirahara K, Sun HW, Wei L, Vahedi G, Kanno Y, O’Shea JJ, Laurence A (2011) Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12(3):247–254PubMedPubMedCentralCrossRef
134.
Alam MS, Maekawa Y, Kitamura A, Tanigaki K, Yoshimoto T, Kishihara K, Yasutomo K (2010) Notch signaling drives IL-22 secretion in CD4+ T cells by stimulating the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A 107(13):5943–5948PubMedPubMedCentralCrossRef
135.
Liu Y, She W, Wang F, Li J, Wang J, Jiang W (2014) 3, 3’-Diindolylmethane alleviates steatosis and the progression of NASH partly through shifting the imbalance of Treg/Th17 cells to Treg dominance. Int Immunopharmacol 23(2):489–498PubMedCrossRef
136.
137.
Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, Kim CH (2015) Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol 8(1):80–93PubMedCrossRef
138.
Hu X, Wang Y, Hao LY, Liu X, Lesch CA, Sanchez BM, Wendling JM, Morgan RW, Aicher TD, Carter LL, Toogood PL, Glick GD (2015) Corrigendum: sterol metabolism controls TH17 differentiation by generating endogenous RORgamma agonists. Nat Chem Biol 11(9):741PubMedCrossRef
139.
Kidani Y, Elsaesser H, Hock MB, Vergnes L, Williams KJ, Argus JP, Marbois BN, Komisopoulou E, Wilson EB, Osborne TF, Graeber TG, Reue K, Brooks DG, Bensinger SJ (2013) Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat Immunol 14(5):489–499PubMedPubMedCentralCrossRef
140.
J.Y. Kim, R. Garcia-Carbonell, S. Yamachika, P. Zhao, D. Dhar, R. Loomba, R.J. Kaufman, A.R. Saltiel, M. Karin, ER Stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P, Cell 175(1) (2018) 133–145 e15.
141.
Ma HY, Yamamoto G, Xu J, Liu X, Karin D, Kim JY, Alexandrov LB, Koyama Y, Nishio T, Benner C, Heinz S, Rosenthal SB, Liang S, Sun M, Karin G, Zhao P, Brodt P, McKillop IH, Quehenberger O, Dennis E, Saltiel A, Tsukamoto H, Gao B, Karin M, Brenner DA, Kisseleva T (2020) IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J Hepatol 72(5):946–959PubMedCrossRef
142.
Cui G, Qin X, Wu L, Zhang Y, Sheng X, Yu Q, Sheng H, Xi B, Zhang JZ, Zang YQ (2011) Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J Clin Investig 121(2):658–670PubMedPubMedCentralCrossRef
143.
Karmaus PWF, Chen X, Lim SA, Herrada AA, Nguyen TM, Xu B, Dhungana Y, Rankin S, Chen W, Rosencrance C, Yang K, Fan Y, Cheng Y, Easton J, Neale G, Vogel P, Chi H (2019) Metabolic heterogeneity underlies reciprocal fates of TH17 cell stemness and plasticity. Nature 565(7737):101–105PubMedCrossRef
144.
Haghikia A, Jorg S, Duscha A, Berg J, Manzel A, Waschbisch A, Hammer A, Lee DH, May C, Wilck N, Balogh A, Ostermann AI, Schebb NH, Akkad DA, Grohme DA, Kleinewietfeld M, Kempa S, Thone J, Demir S, Muller DN, Gold R, Linker RA (2015) Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity 43(4):817–829PubMedCrossRef
145.
Allen MJ, Fan YY, Monk JM, Hou TY, Barhoumi R, McMurray DN, Chapkin RS (2014) n-3 PUFAs reduce T-helper 17 cell differentiation by decreasing responsiveness to interleukin-6 in isolated mouse splenic CD4(+) T cells. J Nutr 144(8):1306–1313PubMedPubMedCentralCrossRef
146.
Dejani NN, Orlando AB, Nino VE, Penteado LA, Verdan FF, Bazzano JMR, Codo AC, Salina ACG, Saraiva AC, Avelar MR, Spolidorio LC, Serezani CH, Medeiros AI (2018) Intestinal host defense outcome is dictated by PGE2 production during efferocytosis of infected cells. Proc Natl Acad Sci U S A 115(36):E8469–E8478PubMedPubMedCentralCrossRef
147.
Kachler K, Bailer M, Heim L, Schumacher F, Reichel M, Holzinger CD, Trump S, Mittler S, Monti J, Trufa DI, Rieker RJ, Hartmann A, Sirbu H, Kleuser B, Kornhuber J, Finotto S (2017) Enhanced acid sphingomyelinase activity drives immune evasion and tumor growth in non-small cell lung carcinoma. Can Res 77(21):5963–5976CrossRef
148.
Thomas K, Sehr T, Proschmann U, Rodriguez-Leal FA, Haase R, Ziemssen T (2017) Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. J Neuroinflammation 14(1):41PubMedPubMedCentralCrossRef
149.
M.O. Johnson, M.M. Wolf, M.Z. Madden, G. Andrejeva, A. Sugiura, D.C. Contreras, D. Maseda, M.V. Liberti, K. Paz, R.J. Kishton, M.E. Johnson, A.A. de Cubas, P. Wu, G. Li, Y. Zhang, D.C. Newcomb, A.D. Wells, N.P. Restifo, W.K. Rathmell, J.W. Locasale, M.L. Davila, B.R. Blazar, J.C. Rathmell, Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism, Cell 175(7) (2018) 1780–1795 e19.
150.
Seto WK, Lo YR, Pawlotsky JM, Yuen MF (2018) Chronic hepatitis B virus infection. Lancet 392(10161):2313–2324PubMedCrossRef
151.
Spearman CW, Dusheiko GM, Hellard M, Sonderup M (2019) Hepatitis C. Lancet 394(10207):1451–1466PubMedCrossRef
152.
Chang Q, Wang YK, Zhao Q, Wang CZ, Hu YZ, Wu BY (2012) Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C. J Gastroenterol Hepatol 27(2):273–278PubMedCrossRef
153.
Ge J, Wang K, Meng QH, Qi ZX, Meng FL, Fan YC (2010) Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol 30(1):60–67PubMedCrossRef
154.
D. Feng, X. Kong, H. Weng, O. Park, H. Wang, S. Dooley, M.E. Gershwin, B. Gao, Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection, Gastroenterology 143(1) (2012) 188–98 e7.
155.
Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF, Robek MD (2011) A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 141(5):1897–1906PubMedCrossRef
156.
Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, Jin L, Fu JL, Shi F, Shi M, Wang HF, Wang FS (2010) Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51(1):81–91PubMedCrossRef
157.
Sun HQ, Zhang JY, Zhang H, Zou ZS, Wang FS, Jia JH (2012) Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. J Viral Hepatitis 19(6):396–403CrossRef
158.
Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, Chen SJ (2013) Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol 8:40PubMedPubMedCentralCrossRef
159.
Wang J, Liu Y, Xie L, Li S, Qin X (2016) Association of IL-17A and IL-17F gene polymorphisms with chronic hepatitis B and hepatitis B virus-related liver cirrhosis in a Chinese population: a case-control study. Clin Res Hepatol Gastroenterol 40(3):288–296PubMedCrossRef
160.
Sertorio M, Hou X, Carmo RF, Dessein H, Cabantous S, Abdelwahed M, Romano A, Albuquerque F, Vasconcelos L, Carmo T, Li J, Varoquaux A, Arnaud V, Oliveira P, Hamdoun A, He H, Adbelmaboud S, Mergani A, Zhou J, Monis A, Pereira LB, Halfon P, Bourliere M, Parana R, Dos Reis M, Gonnelli D, Moura P, Elwali NE, Argiro L, Li Y, Dessein A (2015) IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections. Hepatology 61(4):1321–1331PubMedCrossRef
161.
Wu LY, Liu S, Liu Y, Guo C, Li H, Li W, Jin X, Zhang K, Zhao P, Wei L, Zhao J (2015) Up-regulation of interleukin-22 mediates liver fibrosis via activating hepatic stellate cells in patients with hepatitis C. Clin Immunol 158(1):77–87PubMedCrossRef
162.
Diehl AM, Day C (2017) Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377(21):2063–2072PubMedCrossRef
163.
Siddique O, Joseph-Talreja M, Yoo ER, Perumpail RB, Cholankeril G, Harrison SA, Younossi ZM, Wong RJ, Ahmed A (2017) Rising rate of liver transplantation in the baby boomer generation with non-alcoholic steatohepatitis in the United States. J Clin Transl Hepatol 5(3):193–196PubMedPubMedCentral
164.
He B, Wu L, Xie W, Shao Y, Jiang J, Zhao Z, Yan M, Chen Z, Cui D (2017) The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice. BMC Immunol 18(1):33PubMedPubMedCentralCrossRef
165.
Nati M, Haddad D, Birkenfeld AL, Koch CA, Chavakis T, Chatzigeorgiou A (2016) The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). Rev Endocr Metab Disord 17(1):29–39PubMedCrossRef
166.
Rau M, Schilling AK, Meertens J, Hering I, Weiss J, Jurowich C, Kudlich T, Hermanns HM, Bantel H, Beyersdorf N, Geier A (2016) Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol 196(1):97–105PubMedCrossRef
167.
Tang Y, Bian Z, Zhao L, Liu Y, Liang S, Wang Q, Han X, Peng Y, Chen X, Shen L, Qiu D, Li Z, Ma X (2011) Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol 166(2):281–290PubMedPubMedCentralCrossRef
168.
M.E. Moreno-Fernandez, D.A. Giles, J.R. Oates, C.C. Chan, M. Damen, J.R. Doll, T.E. Stankiewicz, X. Chen, K. Chetal, R. Karns, M.T. Weirauch, L. Romick-Rosendale, S.A. Xanthakos, R. Sheridan, S. Szabo, A.S. Shah, M.A. Helmrath, T.H. Inge, H. Deshmukh, N. Salomonis, S. Divanovic, PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease, Cell Metab 33(6) (2021) 1187–1204 e9.
169.
Gomes AL, Teijeiro A, Buren S, Tummala KS, Yilmaz M, Waisman A, Theurillat JP, Perna C, Djouder N (2016) Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 30(1):161–175PubMedCrossRef
170.
Zai W, Chen W, Wu Z, Jin X, Fan J, Zhang X, Luan J, Tang S, Mei X, Hao Q, Liu H, Ju D (2019) Targeted interleukin-22 gene delivery in the liver by polymetformin and penetratin-based hybrid nanoparticles to treat nonalcoholic fatty liver disease. ACS Appl Mater Interfaces 11(5):4842–4857PubMedCrossRef
171.
Yang L, Zhang Y, Wang L, Fan F, Zhu L, Li Z, Ruan X, Huang H, Wang Z, Huang Z, Huang Y, Yan X, Chen Y (2010) Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J Hepatol 53(2):339–347PubMedCrossRef
172.
Ma HY, Xu J, Liu X, Zhu Y, Gao B, Karin M, Tsukamoto H, Jeste DV, Grant I, Roberts AJ, Contet C, Geoffroy C, Zheng B, Brenner D, Kisseleva T (2016) The role of IL-17 signaling in regulation of the liver-brain axis and intestinal permeability in alcoholic liver disease. Curr Pathobiol Rep 4(1):27–35PubMedPubMedCentralCrossRef
173.
J. Xu, H.Y. Ma, X. Liu, S. Rosenthal, J. Baglieri, R. McCubbin, M. Sun, Y. Koyama, C.G. Geoffroy, K. Saijo, L. Shang, T. Nishio, I. Maricic, M. Kreifeldt, P. Kusumanchi, A. Roberts, B. Zheng, V. Kumar, K. Zengler, D.P. Pizzo, M. Hosseini, C. Contet, C.K. Glass, S. Liangpunsakul, H. Tsukamoto, B. Gao, M. Karin, D.A. Brenner, G.F. Koob, T. Kisseleva, Blockade of IL-17 signaling reverses alcohol-induced liver injury and excessive alcohol drinking in mice, JCI Insight 5(3) (2020).
174.
Lemmers A, Moreno C, Gustot T, Marechal R, Degre D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Deviere J (2009) The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 49(2):646–657PubMedCrossRef
175.
B. Kasztelan-Szczerbinska, A. Surdacka, K. Celinski, J. Rolinski, A. Zwolak, S. Miacz, M. Szczerbinski, Prognostic significance of the systemic inflammatory and immune balance in alcoholic liver disease with a focus on gender-related differences, PLoS One 10(6) (2015) e0128347.
176.
Lin F, Taylor NJ, Su H, Huang X, Hussain MJ, Abeles RD, Blackmore L, Zhou Y, Ikbal MM, Heaton N, Jassem W, Shawcross DL, Vergani D, Ma Y (2013) Alcohol dehydrogenase-specific T-cell responses are associated with alcohol consumption in patients with alcohol-related cirrhosis. Hepatology 58(1):314–324PubMedCrossRef
177.
W. Shi, Q. Zhu, J. Gu, X. Liu, L. Lu, X. Qian, J. Shen, F. Zhang, G. Li, Anti-IL-17 antibody improves hepatic steatosis by suppressing interleukin-17-related fatty acid synthesis and metabolism, Clin Dev Immunol 2013 (2013) 253046.
178.
Chu S, Sun R, Gu X, Chen L, Liu M, Guo H, Ju S, Vatsalya V, Feng W, McClain CJ, Deng Z (2021) Inhibition of sphingosine-1-phosphate-induced Th17 cells ameliorates alcohol-associated steatohepatitis in mice. Hepatology 73(3):952–967PubMedCrossRef
179.
Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS (2013) Autoimmune hepatitis. Lancet 382(9902):1433–1444PubMedCrossRef
180.
Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D (2004) Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 41(1):31–37PubMedCrossRef
181.
Longhi MS, Ma Y, Mitry RR, Bogdanos DP, Heneghan M, Cheeseman P, Mieli-Vergani G, Vergani D (2005) Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 25(1):63–71PubMedCrossRef
182.
Grant CR, Liberal R, Holder BS, Cardone J, Ma Y, Robson SC, Mieli-Vergani G, Vergani D, Longhi MS (2014) Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology 59(3):1007–1015PubMedCrossRef
183.
Liberal R, Grant CR, Ma Y, Csizmadia E, Jiang ZG, Heneghan MA, Yee EU, Mieli-Vergani G, Vergani D, Robson SC, Longhi MS (2016) CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease. J Autoimmun 72:102–112PubMedPubMedCentralCrossRef
184.
Vuerich M, Harshe R, Frank LA, Mukherjee S, Gromova B, Csizmadia E, Nasser IAM, Ma Y, Bonder A, Patwardhan V, Robson SC, Longhi MS (2021) Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis. J Hepatol 74(1):48–57PubMedCrossRef
185.
M.S. Longhi, M. Vuerich, A. Kalbasi, J.E. Kenison, A. Yeste, E. Csizmadia, B. Vaughn, L. Feldbrugge, S. Mitsuhashi, B. Wegiel, L. Otterbein, A. Moss, F.J. Quintana, S.C. Robson, Bilirubin suppresses Th17 immunity in colitis by upregulating CD39, JCI Insight 2(9) (2017).
186.
Gulamhusein AF, Hirschfield GM (2020) Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol 17(2):93–110PubMedCrossRef
187.
Qian C, Jiang T, Zhang W, Ren C, Wang Q, Qin Q, Chen J, Deng A, Zhong R (2013) Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis. Cytokine 64(1):172–180PubMedCrossRef
188.
Rong G, Zhou Y, Xiong Y, Zhou L, Geng H, Jiang T, Zhu Y, Lu H, Zhang S, Wang P, Zhang B, Zhong R (2009) Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol 156(2):217–225PubMedPubMedCentralCrossRef
189.
T. Shi, T. Zhang, L. Zhang, Y. Yang, H. Zhang, F. Zhang, The distribution and the fibrotic role of elevated inflammatory Th17 cells in patients with primary biliary cirrhosis, Medicine 94(44) (2015) e1888.
190.
Yang CY, Ma X, Tsuneyama K, Huang S, Takahashi T, Chalasani NP, Bowlus CL, Yang GX, Leung PS, Ansari AA, Wu L, Coppel RL, Gershwin ME (2014) IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology 59(5):1944–1953PubMedCrossRef
191.
K. Kawata, M. Tsuda, G.X. Yang, W. Zhang, H. Tanaka, K. Tsuneyama, P. Leung, X.S. He, S. Knechtle, A.A. Ansari, R.L. Coppel, M.E. Gershwin, Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis, PloS one 8(9) (2013) e74225.
192.
H.J. Cordell, Y. Han, G.F. Mells, Y. Li, G.M. Hirschfield, C.S. Greene, G. Xie, B.D. Juran, D. Zhu, D.C. Qian, J.A. Floyd, K.I. Morley, D. Prati, A. Lleo, D. Cusi, U.S.P.B.C.C. Canadian, P.B.C.G.S.G. Italian, U.-P. Consortium, M.E. Gershwin, C.A. Anderson, K.N. Lazaridis, P. Invernizzi, M.F. Seldin, R.N. Sandford, C.I. Amos, K.A. Siminovitch, International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways, Nat Commun 6 (2015) 8019.
193.
Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M (2018) Primary sclerosing cholangitis. Lancet 391(10139):2547–2559PubMedCrossRef
194.
Sabino J, Vieira-Silva S, Machiels K, Joossens M, Falony G, Ballet V, Ferrante M, Van Assche G, Van der Merwe S, Vermeire S, Raes J (2016) Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 65(10):1681–1689PubMedCrossRef
195.
Katt J, Schwinge D, Schoknecht T, Quaas A, Sobottka I, Burandt E, Becker C, Neurath MF, Lohse AW, Herkel J, Schramm C (2013) Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. Hepatology 58(3):1084–1093PubMedCrossRef
196.
Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, Fleming TR, Fisher LD, Beaver SJ, LaRusso NF (1989) Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 10(4):430–436PubMedCrossRef
197.
S. Lemoinne, A. Kemgang, K. Ben Belkacem, M. Straube, S. Jegou, C. Corpechot, I.B.D.N. Saint-Antoine, O. Chazouilleres, C. Housset, H. Sokol, Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis, Gut 69(1) (2020) 92–102.
198.
Kummen M, Holm K, Anmarkrud JA, Nygard S, Vesterhus M, Hoivik ML, Troseid M, Marschall HU, Schrumpf E, Moum B, Rosjo H, Aukrust P, Karlsen TH, Hov JR (2017) The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 66(4):611–619PubMedCrossRef
199.
Torres J, Bao X, Goel A, Colombel JF, Pekow J, Jabri B, Williams KM, Castillo A, Odin JA, Meckel K, Fasihuddin F, Peter I, Itzkowitz S, Hu J (2016) The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther 43(7):790–801PubMedPubMedCentralCrossRef
200.
Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD (2013) Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 37(6):604–612PubMedCrossRef
201.
Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T, Suzuki T, Koda Y, Chu PS, Taniki N, Yamaguchi A, Kanamori M, Kamada N, Hattori M, Ashida H, Sakamoto M, Atarashi K, Narushima S, Yoshimura A, Honda K, Sato T, Kanai T (2019) Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol 4(3):492–503PubMedCrossRef
202.
Hernandez-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. Annu Rev Pathol 6:425–456PubMedCrossRef
203.
Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, Wang X, Ryffel B, Sun B (2013) IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol 191(4):1835–1844PubMedCrossRef
204.
Goossens N, Hoshida Y (2016) Is hepatocellular cancer the same disease in alcoholic and nonalcoholic fatty liver diseases? Gastroenterology 150(8):1710–1717PubMedCrossRef
205.
Fabre T, Kared H, Friedman SL, Shoukry NH (2014) IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-beta receptor on hepatic stellate cells in a JNK-dependent manner. J Immunol 193(8):3925–3933PubMedCrossRef
206.
T. Fabre, M.F. Molina, G. Soucy, J.P. Goulet, B. Willems, J.P. Villeneuve, M. Bilodeau, N.H. Shoukry, Type 3 cytokines IL-17A and IL-22 drive TGF-beta-dependent liver fibrosis, Sci Immunol 3(28) (2018).
207.
Zhao J, Zhang Z, Luan Y, Zou Z, Sun Y, Li Y, Jin L, Zhou C, Fu J, Gao B, Fu Y, Wang FS (2014) Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology 59(4):1331–1342PubMedCrossRef
208.
Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, Gao B (2012) Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 56(3):1150–1159PubMedCrossRef
209.
Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50(5):980–989PubMedCrossRef
210.
Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114(6):1141–1149PubMedPubMedCentralCrossRef
211.
Liang KH, Lai MW, Lin YH, Chu YD, Lin CL, Lin WR, Huang YH, Wang TH, Chien RN, Hu TH, Yeh CT (2021) Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients. BMC Gastroenterol 21(1):177PubMedPubMedCentralCrossRef
212.
Qian X, Chen H, Wu X, Hu L, Huang Q, Jin Y (2017) Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine 89:34–44PubMedCrossRef
213.
Beringer A, Noack M, Miossec P (2016) IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med 22(3):230–241PubMedCrossRef
214.
Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W, Schlereth B, Locher M, Bertschinger J, Grabulovski D (2016) Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs 8(1):141–149PubMedCrossRef
215.
Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P, Watling MIL, Yeremenko N, Miossec P, Shaw S (2018) Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis 77(4):523–532PubMedCrossRef
216.
Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM (2012) A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 132(2):304–314PubMedCrossRef
217.
A.B. Kimball, K.B. Gordon, R.G. Langley, A. Menter, E.K. Chartash, J. Valdes, A.B.T.P.S. Investigators, Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial, Arch Dermatol 144(2) (2008) 200–7.
218.
C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, Y. Wang, S. Li, L.T. Dooley, K.B. Gordon, P.s. investigators, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1), Lancet 371(9625) (2008) 1665–74.
219.
K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding, C. Guzzo, M.C. Hsu, Y. Wang, S. Li, L.T. Dooley, K. Reich, P.s. investigators, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), Lancet 371(9625) (2008) 1675–84.
220.
Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka TM, Roush WR, Vidovic D, Schurer SC, Xu J, Wagoner G, Drew PD, Griffin PR, Burris TP (2011) Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472(7344):491–494PubMedPubMedCentralCrossRef
221.
Isono F, Fujita-Sato S, Ito S (2014) Inhibiting RORgammat/Th17 axis for autoimmune disorders. Drug Discov Today 19(8):1205–1211PubMedCrossRef
Metadaten
Titel
Th17 cells in the liver: balancing autoimmunity and pathogen defense
verfasst von
Nobuhito Taniki
Nobuhiro Nakamoto
Po-Sung Chu
Masataka Ichikawa
Toshiaki Teratani
Takanori Kanai
Publikationsdatum
24.02.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Seminars in Immunopathology / Ausgabe 4/2022
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-022-00917-9

Weitere Artikel der Ausgabe 4/2022

Seminars in Immunopathology 4/2022 Zur Ausgabe

Review

TNF in the liver: targeting a central player in inflammation

Review

The intestinal and biliary microbiome in autoimmune liver disease—current evidence and concepts

Review

B cells in autoimmune hepatitis: bystanders or central players?

Introduction

Tolerance and autoimmunity in the liver

Review

Bile acids and their receptors: modulators and therapeutic targets in liver inflammation

Review

MAIT cells in liver inflammation and fibrosis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise